Welcome to our dedicated page for SS Innovations news (Ticker: SSII), a resource for investors and traders seeking the latest updates and insights on SS Innovations stock.
SS Innovations International Inc. (Nasdaq: SSII) is a commercial-stage surgical robotics company that develops the SSi Mantra surgical robotic system and SSi Mudra surgical instruments. Company news frequently highlights progress toward its stated goal of making robotic surgery more affordable and accessible to a larger segment of the global population.
News updates for SSII often cover developments related to the SSi Mantra platform, including new installations, clinical milestones, and telesurgery achievements. The company has reported thousands of surgical procedures performed using the SSi Mantra, including cardiac procedures and telesurgeries across categories such as pediatric, urology, gynecology, oncology, and general surgery. Announcements have also described the introduction of smaller 5-millimeter instruments designed for pediatric, cardiac, and head and neck surgery, as well as the use of the SSi Mantra Tele Surgeon Console for remote procedures.
Investors and healthcare professionals following SS Innovations can expect news on quarterly and annual financial results, including revenue from system sales, instrument sales, warranty sales, and lease income. Regulatory and clinical updates are another recurring theme, such as the completion of a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and the submission of a 510(k) premarket notification to the U.S. Food and Drug Administration for multiple specialty indications.
This news feed aggregates press releases, SEC-related announcements, and other public communications from SS Innovations. It provides a single location to review updates on product developments, clinical experience, regulatory milestones, and corporate events related to SSII and its surgical robotic technologies.
SS Innovations (NASDAQ: SSII) has achieved a significant milestone with its SSi Mantra surgical robotic system, successfully completing over 4,000 robotic surgeries across more than 100 types of procedures with zero complications. Notable achievements include 215 cardiac surgical procedures, with six performed via telesurgery across India using the SSi Mantra 3 system.
The system is currently approved in seven countries including India, Nepal, Ecuador, Guatemala, Philippines, Indonesia, and Ukraine. The company is pursuing market expansion with expected European Union CE Mark decision by late 2025 and FDA approval targeted for first half of 2026. The SSi Mantra system supports various surgical specialties including general surgery, urology, gynecology, cardiac, gastrointestinal, thoracic, head and neck, and breast and plastic procedures.
SS Innovations International (NASDAQ: SSII) announced plans to submit a De Novo Classification Request to the FDA for its SSi Mantra 3 surgical robotic system in July 2025. The company has demonstrated significant market traction with 80 SSi Mantra systems installed across 75 hospitals since August 2022, facilitating over 3,800 surgeries. The newer SSi Mantra 3 version, launched in June 2024, has 37 installations and has been used in more than 750 procedures, including 70 cardiac cases, with no device-related complications.
The FDA submission will seek approval for multiple surgical specialties including urology, gynecology, general surgery, and thoracic and cardiac surgery. The system is currently approved in six countries, and the company is simultaneously pursuing EU CE Mark approval.
SS Innovations International (NASDAQ: SSII), a surgical robotics technology company, has announced a planned CFO transition. Arvind Palaniappan has been appointed as Interim CFO effective May 1, 2025, replacing Anup Sethi, who served as CFO during the company's growth phase. Under Sethi's seven-year tenure, the company successfully launched over 80 surgical robotic systems in India and internationally, and recently achieved a milestone with its Nasdaq uplisting on April 25. The company has initiated a search for a permanent CFO, while Sethi will remain available in an advisory capacity during the transition period.
SS Innovations International (SSII) has received approval to uplist from OTC to Nasdaq Capital Market, with trading set to commence on April 25, 2025, under the same ticker 'SSII'. The company, focused on affordable surgical robotic technologies, reported significant achievements with its SSi Mantra surgical robotic system:
Key highlights include:
- Installation of 80 systems across 75 hospitals in India and other countries
- 3,500+ successful surgeries, including 195+ cardiac procedures with zero device-related complications
- First Indian company to receive CDSCO approval for telesurgery
- Completed 16 telesurgeries, including world's first robotic cardiac telesurgeries at distances up to 1,200 miles
The company reported strong financial performance with revenue of $20.6 million for 2024, a 251% increase from 2023's $5.9 million, and improved gross margin from 12.3% to 40.9%. SSII is pursuing EU CE Mark and U.S. FDA approval, expected in late 2025 and early 2026, respectively.
SS Innovations International (SSII) has reported significant achievements in 2024, with its SSi Mantra surgical robotic system completing over 3,500 surgeries across 80 installations in 75 hospitals. The company sold 37 systems and installed 8 more on a Pay-Per-Use Lease model in 2024.
Preliminary unaudited results show expected 2024 revenues of over US$22 million, representing a nearly four-fold increase from 2023. Gross margins improved from 12.30% to 36.90%. For Q1 2025, SSII anticipates reaching 78 installations with estimated revenues of US$6.4 million and 45% gross margin.
Key achievements include: zero device-related complications across all procedures, successful telesurgery implementation with 16 procedures completed, expansion of manufacturing capacity to 20 units monthly, training of over 750 surgeons, and regulatory approvals in multiple countries. The company expects FDA and CE approvals by late 2025 or early 2026.
SS Innovations International (OTC: SSII) has secured regulatory approvals for its SSi Mantra 3 Surgical Robotic System in both the Philippines and Ukraine. The company partnered with RBGM Medical Express Sales Inc. in Manila and Loran Group in Kiev for distribution.
The Philippines market, with nearly 4,000 hospitals, represents a significant opportunity for expanding robotic surgery access. In Ukraine, despite ongoing conflict and damaged medical facilities, the Certificate of Conformity approval positions SSII to participate in the country's medical infrastructure rebuilding efforts.
The SSi Mantra 3 system features 3-5 robotic arms, 3D 4K monitoring, and over 40 different types of robotic endo-surgical instruments. It has been clinically validated in India across 80+ surgical procedures. The company anticipates receiving FDA and CE Mark approvals in the second half of 2025.
SS Innovations International (OTC: SSII) has achieved a significant milestone by successfully performing India's first North-to-South robotic cardiac telesurgery using its SSi Mantra 3 Surgical Robotic System. The procedure connected the company's headquarters in Gurugram to Aster CMI Hospital in Bengaluru, spanning over 2,000 kilometers.
The 2-hour-40-minute surgery involved closing a complex Atrial Septal Defect in a 35-year-old patient. Led by Dr. Sudhir Srivastava from Gurugram and supported by Dr. Arul Furtado's team in Bengaluru, the procedure demonstrated exceptional precision with minimal latency.
The SSi Mantra 3, India's first CDSCO-approved surgical robotic system for telesurgery, represents a significant advancement in making specialized surgical care accessible across long distances. This achievement follows previous successful telesurgeries spanning 40 km and 286 km, marking a substantial leap in remote surgical capabilities.
SS Innovations International (OTC: SSII) unveiled its groundbreaking SSI Mantra Tele-Sync Mobile Unit (SSI MantraM) at the Second Global Multi-Specialty Robotic Surgery Conference in Gurugram, India. This first-of-its-kind mobile tele-surgical unit integrates the SSi Mantra 3 Surgical Robotic System with high-speed connectivity to enable remote surgical procedures.
The conference attracted over 1,200 medical professionals. The SSI MantraM is designed to provide robotic-assisted surgery to underserved communities through telesurgery capabilities and real-time collaboration between remote and on-site surgical teams. Notably, the SSi Mantra 3 system is the only robotic system globally to receive CDSCO regulatory approval for telesurgery and tele-proctoring.
The system features 3-5 robotic arms, 3D 4K monitoring, and supports over 40 different types of robotic endo-surgical instruments across various specialties. The company anticipates receiving FDA and CE Mark approval in the second half of 2025.